PODD
Insulet CorporationNASDAQHealth CareMedical DevicesSnapshot 2026-05-08
As of May 8, 2026, PODD has a composite score of 21.1 and a signal label of "mild_favorable." The company momentum score significantly increased by 60.1 points to 74.8, while the composite insight score rose by 13.4 points to 21.1. This analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.17
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.44 → $1.44 (-0.1% / 30d). 0 raised, 1 cut, 19 covering analysts.
0 upgrades, 1 downgrade / 30d, 12 maintained. 83% of analysts rate Buy.
13 PT revisions / 30d. Avg target 49.6% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
7 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase revenue growth outlookgrowthbehind6% progress
5/6: “We are raising our total company revenue growth outlook to reflect our progress.”
Why this status
Stated in 3 of last 3 quarters. Revenue grew from $441.7M in 2025-Q1 to $706.3M in 2025-Q3. Management has consistently raised the revenue growth outlook, indicating a positive trajectory.
- 2.Share repurchase program expansioncapital allocationmixed25% progress
2/18: “Board approved a $350 million increase in the previously authorized $125 million stock repurchase authorization.”
Why this status
Newly stated in 2026-Q1. The Board approved a $350 million increase in the stock repurchase authorization, expanding the total authorization to $475 million. This indicates a strategic focus on capital allocation through share buybacks.
- 3.Maintain gross margin above 71%costwatchprovisional
11/6: “Gross Margin >71%.”
Why this status
Stated in 2 of last 2 quarters. Management has consistently aimed to maintain a gross margin above 71%. The focus on cost management is evident, but specific margin figures for recent quarters are not provided in the inputs.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 61%; 252d 41%.
Drawdown — Max 1y −57%. Bad day move −4%.
Beta to sector ETF (XLV) — 0.52 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 31/100, drawdown 0/100, beta 52/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- score change · company_momentum_scoreseverity 100
Company momentum rose by 60.1 points (from 14.7 to 74.8).
- score change · composite_insight_scoreseverity 27
Composite insight rose by 13.4 points (from 7.7 to 21.1).
- label change · signal_labelseverity 20
Signal changed from 'mixed' to 'mild_favorable'.
As of May 8, 2026, the company momentum score for PODD rose by 60.1 points, increasing from 14.7 to 74.8. The composite insight score also increased by 13.4 points, moving from 7.7 to 21.1. Additionally, the signal label changed from 'mixed' to 'mild_favorable'.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase revenue growth outlook
GrowthNew since 2026-05-06Management has raised the revenue growth outlook for fiscal year 2026.
BehindStated in 3 of last 3 quarters. Revenue grew from $441.7M in 2025-Q1 to $706.3M in 2025-Q3. Management has consistently raised the revenue growth outlook, indicating a positive trajectory.
Revenue grew from $441.7M in 2025-Q1 to $706.3M in 2025-Q36%CEO/CFO:“We are raising our total company revenue growth outlook to reflect our progress.”Multiple sourcesSource dated 2026-05-06Stated 3 of last 8 quartersFirst seen 2026-05-06Show history (3)
- 2026-Q1Multiple sources
“We are raising our total company revenue growth outlook to reflect our progress.”
- 2025-Q4Multiple sources
“FY 2026 Guidance... Total 20% - 22%”
- 2025-Q3Multiple sources
“FY 2025 Guidance (as of 11/6/2025) Total 28% - 29%.”
- #2
Share repurchase program expansion
Capital allocationThe Board approved a $350 million increase in the stock repurchase authorization.
MixedNewly stated in 2026-Q1. The Board approved a $350 million increase in the stock repurchase authorization, expanding the total authorization to $475 million. This indicates a strategic focus on capital allocation through share buybacks.
25%CEO/CFO:“Board approved a $350 million increase in the previously authorized $125 million stock repurchase authorization.”Multiple sourcesSource dated 2026-02-18Stated 1 of last 8 quartersFirst seen 2026-02-18Show history (1)
- 2026-Q1Multiple sources
“Board approved a $350 million increase in the previously authorized $125 million stock repurchase authorization.”
- #3
Maintain gross margin above 71%
CostManagement aims to maintain a gross margin above 71% for fiscal year 2025.
WatchStated in 2 of last 2 quarters. Management has consistently aimed to maintain a gross margin above 71%. The focus on cost management is evident, but specific margin figures for recent quarters are not provided in the inputs.
No scoreCEO/CFO:“Gross Margin >71%.”Multiple sourcesSource dated 2025-11-06Stated 2 of last 8 quartersFirst seen 2025-11-06provisionalShow history (2)
- 2025-Q3Multiple sources
“Gross Margin >71%.”
- 2025-Q2Multiple sources
“Gross Margin ~71.0%”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
65 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
PODD Insulet Corporation | +21 | full | elevated |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-05-06)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-062d agoItem 2.02
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
earnings preannouncementnegativescore 75 - 2026-03-121mo agoItem 7.01
Regulation FD Disclosure On March 12, 2026, Insulet Corporation (the “Company”) issued a press release regarding a voluntary medical device correction. A copy of the press release is furnished herewith as Exhibit 99.1. While it is too early to ascertain the exact cost of the voluntary medical device correction, the Company currently expects to incur up to $40 million of costs associated with this event, all in 2026. These costs will be excluded from adjusted results. Accordingly, Insulet is n…
legal regulatorynegativescore 14 - 2026-03-042mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 27, 2026, Insulet Corporation (the “Company”) entered into a severance agreement and release (the “Severance Agreement”) with Ana M. Chadwick, the Company’s former Chief Financial Officer. The Severance Agreement does not provide for any material compensation or benefits terms that differ from, or are in addition to, those previously dis…
executive changeneutralscore 13 - 2026-02-242mo agoItem 4.01
Changes in Registrant’s Certifying Accountant On December 15, 2025, the Audit Committee of the Board of Directors of the Company notified GT, the Company’s then independent registered public accounting firm, that the Audit Committee selected PwC as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. GT was previously engaged to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2025. The…
legal regulatorynegativescore 12 - 2026-02-182mo agoItem 2.02
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
earnings preannouncementneutralscore 11
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.